Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 May;21(5):473–480. doi: 10.1111/j.1365-2125.1986.tb02828.x

A simple borohydride/GC method for measuring sparteine metabolites in man.

T Inaba, A Vinks, S V Otton
PMCID: PMC1401017  PMID: 3718806

Abstract

A simple borohydride/GC method was developed for phenotyping sparteine oxidation in man. The major metabolites of sparteine found in human urine, 2- and 5-dehydrosparteine, were converted quantitatively back to sparteine by sodium borohydride reduction. The amount of sparteine metabolites can be estimated from the difference of sparteine concentrations between the borohydride-treated and untreated urine samples. The coefficient of variation of this assay was estimated from repeated analyses to be +/- 3% within a day (intra-assay) and +/- 8% between days (inter-assay).

Full text

PDF
473

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvan G., von Bahr C., Seidemann P., Sjöqvist F. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet. 1982 Feb 6;1(8267):333–333. doi: 10.1016/s0140-6736(82)91583-5. [DOI] [PubMed] [Google Scholar]
  2. Eichelbaum M., Bertilsson L., Säwe J., Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther. 1982 Feb;31(2):184–186. doi: 10.1038/clpt.1982.29. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
  4. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  5. Inaba T., Otton S. V., Kalow W. Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther. 1980 Apr;27(4):547–549. doi: 10.1038/clpt.1980.77. [DOI] [PubMed] [Google Scholar]
  6. Inaba T., Vinks A., Otton S. V., Kalow W. Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther. 1983 Mar;33(3):394–399. doi: 10.1038/clpt.1983.51. [DOI] [PubMed] [Google Scholar]
  7. Kalow W. Pharmacoanthropology: drug metabolism. Fed Proc. 1984 May 15;43(8):2326–2331. [PubMed] [Google Scholar]
  8. Lennard M. S., Silas J. H., Freestone S., Ramsay L. E., Tucker G. T., Woods H. F. Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560. doi: 10.1056/NEJM198212163072505. [DOI] [PubMed] [Google Scholar]
  9. Lewis R. V., Lennard M. S., Jackson P. R., Tucker G. T., Ramsay L. E., Woods H. F. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1985 Mar;19(3):329–333. doi: 10.1111/j.1365-2125.1985.tb02651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  11. Otton S. V., Inaba T., Mahon W. A., Kalow W. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. Can J Physiol Pharmacol. 1982 Jan;60(1):102–105. doi: 10.1139/y82-017. [DOI] [PubMed] [Google Scholar]
  12. Vinks A., Inaba T., Otton S. V., Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther. 1982 Jan;31(1):23–29. doi: 10.1038/clpt.1982.4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES